[1] “IMI 2 JU is a public-private partnership that was established as a `Joint Undertaking` between the European Union and the European Pharmaceutical Industry Association and Associations (EFPIA).” The two members of the Management Board, the main decision-making body of IMI 2 JU, are represented in the same way. See europa.eu/european-union/about-eu/agencies/imi2_en. Do you need more information on preparing and signing grant agreements? Watch this Horizon 2020 webinar for coordinators of successful proposals. Three Joint Technology Initiatives (JTI) – Clean Sky 2, ECSEL and the Innovative Medicine Initiative (IMI) 2 – make available on their websites a separate model consortium agreement for funded projects. These models take into account, in particular, the partial derogations provided for in IPRs, for example. B as regards intellectual property rights in IMI 2. All project partners must sign a consortium agreement defining the rights and obligations of the participants and addressing issues such as governance, accountability and intellectual property rights. The agreement should be tailored to the needs of each project.. . .

.